Evaluating liver stiffness to predict immunotherapy response in liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of transient elastography, known as Fibroscan, in predicting how patients with advanced Hepatocellular carcinoma (HCC) respond to immunotherapy over a six-month period. Participants will undergo a series of evaluations, including clinical examinations, laboratory tests, and imaging studies, to monitor liver fibrosis and other health indicators. The study will track changes in liver condition, complications, and overall survival rates to determine the predictive value of Fibroscan in this context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for immunotherapy.
* Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis).
* Patients with performance status ≤2 at staging work-up.
* absence of high-risk stigmata for bleeding on upper endoscopy, e.g. properly treated oesophageal varices and no history of variceal bleeding, in order to minimise bleeding risk.

Exclusion Criteria:

* Prior locoregional therapy or liver transplantation.
* Child-Pugh class C patients.
* Patients with performance status \>2 at staging work-up.
* Vascular disorders, arterial hypertension, and risk of variceal bleeding.
* Severe autoimmune disorders.
* Patients who lost follow-up.
* Pregnant or breastfeeding women.
* Unwilling to participate in our study.

Where it's running

• Tanta University Hospitals
  Tanta, Gharbyea, Egypt Recruiting

Study contacts

• Principal investigator: Nabila A Elgazzar, MD — Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
• Study coordinator: Rania M Elkafoury, MD
• Email: rania.elkafoury@med.tanta.edu.eg
• Phone: +201004672358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer

  This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07927452

• Impact of Anesthesia on Inflammation and NETosis During HCC Ablation

  This study tests whether a propofol–fentanyl anesthesia plan with lidocaine during radiofrequency ablation for hepatocellular carcinoma affects inflammation and NETosis in patients with small tumors.

  Recruiting Iuliu Hatieganu University of Medicine and Pharmacy · Cluj-Napoca, Cluj · NCT07657897

• Pre-emptive topical indomethacin to prevent sorafenib-related hand-foot syndrome in advanced liver cancer

  This trial will test whether applying 1% indomethacin gel to both hands twice daily can reduce hand-foot syndrome in adults with advanced hepatocellular carcinoma starting sorafenib.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT07560566

• Becotatug vedotin (MRG003) for previously treated advanced liver cancer with EGFR testing

  This study will test whether Becotatug vedotin (MRG003) helps people with advanced hepatocellular carcinoma whose cancer progressed after PD‑1/L1 therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07536789

• TACE or Ablation With Sintilimab and Ipilimumab Before Surgery for Liver Cancer

  This study tests whether combining local tumor treatments with immunotherapy before surgery helps people with resectable hepatocellular carcinoma at higher risk of recurrence.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07487662

• Personalized adaptive second-line treatments for advanced liver cancer

  This trial tries different personalized second-line treatments to find which work best for people with advanced hepatocellular carcinoma after first-line immunotherapy-based regimens stop working.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07328009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.